| 30/12/2020 |
Change of Director’s Interest Notice – Gordon |
| 30/12/2020 |
Change of Director’s Interest Notice – Halasz |
| 30/12/2020 |
Change of Director’s Interest Notice – King |
| 24/12/2020 |
Confirming Changes to the Cellmid Board |
| 23/12/2020 |
Newsletter |
| 16/12/2020 |
Appendix 2A |
| 16/12/2020 |
Change of Director’s Interest Notice – Eck |
| 14/12/2020 |
Cellmid Signs 10 Year Chinese Distribution Agreement |
| 02/12/2020 |
Final Director’s Interest Notice – Walton |
| 02/12/2020 |
Initial Director’s Interest Notice – Eck-Thompson |
| 30/11/2020 |
AGM Presentation to Shareholders |
| 30/11/2020 |
Annual General Meeting – Change of Agenda |
| 30/11/2020 |
Results of Meeting |
| 23/11/2020 |
Annual General Meeting Update |
| 12/11/2020 |
Growth Strategy Presentation |
| 05/11/2020 |
Release of Shares from Voluntary Escrow |
| 01/11/2020 |
Letter to Shareholders – Notice of Annual General Meeting |
| 01/11/2020 |
Notice of Annual General Meeting/Proxy Form |
| 21/10/2020 |
Appendix 4C and Quarterly Activity Report |
| 21/10/2020 |
Board Renewal To Align With Consumer Health Growth Strategy |
| 14/10/2020 |
2020 Annual General Meeting |
| 07/10/2020 |
Section 249D Notice |
| 15/09/2020 |
2020 Annual Report to shareholders |
| 15/09/2020 |
Appendix 4G and Corporate Governance Statement |
| 10/09/2020 |
CDY Engages Advisers to Facilitate Divestment from Lyramid |
| 27/08/2020 |
Appendix 4E and FY20 Financial Report |
| 27/08/2020 |
FY20 Financial Results |
| 27/08/2020 |
FY20 Results Presentation |
| 28/07/2020 |
Cellmid signed exclusive agreement with premium salon distributor in the USA |
| 22/07/2020 |
Cellmid Appendix 4C-Q4 FY2020 Business Activity |
| 09/07/2020 |
ASX Aware query |
| 09/07/2020 |
Cellmid signs exclusive agreement for SARS-CoV-2 laboratory tests |
| 07/07/2020 |
Market release – Pause in trading |
| 05/07/2020 |
Extension of Wondfo Sars-coV-2 rapid test distribution agreement |
| 23/06/2020 |
Appendix 3Y – Change of Director’s Interest Notice |
| 18/06/2020 |
Appendix 2A – Application for quotation of +securities |
| 18/06/2020 |
Appendix 3G – Notification of issue, conversion or payment up of equity +securities |
| 18/06/2020 |
Appendix 3Y – Change of Director’s Interest Notice |
| 18/06/2020 |
Appendix 3Y – Change of Director’s Interest Notice |
| 18/06/2020 |
Form 604 – Notice of change of interests of substantial holder |
| 16/06/2020 |
Cellmid reports on strong QVC sales event |
| 15/06/2020 |
Cellmid reports on results of the Doherty Institute testing |
| 04/06/2020 |
Cellmid signs introducer agreement to broaden product offering |
| 01/06/2020 |
Cellmid appoints Dr Dominic Burg as Chief Operating Officer |
| 22/05/2020 |
General Meeting – May 2020 |
| 22/05/2020 |
Results of May 2020 General Meeting |
| 15/05/2020 |
Company update and extension of voluntary suspension |
| 14/05/2020 |
Amendment to notice of general meeting |
| 11/05/2020 |
Cellmid Limited (ASX: CDY) – Suspension from Official Quotation |
| 07/05/2020 |
Cellmid Limited (ASX: CDY) – Trading Halt |
| 07/05/2020 |
Pause in Trading |
| 04/05/2020 |
Appendix 2A – Application for quotation of +securities |
| 04/05/2020 |
Cellmid share purchase plan completed |
| 30/04/2020 |
Cellmid’s Alopecia patent allowed in Australia and Japan |
| 27/04/2020 |
Cellmid Appendix 4C – Q3 FY2020 business activity |
| 22/04/2020 |
Independent test results for the Wondfo Sars-Cov2 Test |
| 22/04/2020 |
Notice of May 2020 General Meeting |
| 16/04/2020 |
Share Purchase Plan |
| 14/04/2020 |
Appendix 2A – Application for quotation of +securities |
| 14/04/2020 |
Cellmid’s shipment of Sars-Cov2 test received |
| 14/04/2020 |
Market Release – Pause in Trading |
| 08/04/2020 |
An offer of +securities under a +securities purchase plan |
| 07/04/2020 |
Cellmid Limited (ASX: CDY) – Reinstatement to Official Quotation |
| 07/04/2020 |
Cellmid share placement raises $6 million |
| 07/04/2020 |
Total number of +securities proposed to be issued for a placement or other type of issue |
| 06/04/2020 |
Cellmid Limited (ASX: CDY) – Suspension from Official Quotation |
| 01/04/2020 |
Cellmid Limited (ASX: CDY) – Trading Halt |
| 28/03/2020 |
Cellmid Signs COVID-19 Rapid Diagnostic Supply Agreement |
| 28/03/2020 |
Market Update on COVID-19 |
| 28/03/2020 |
Reinstatement to Official Quotation |
| 06/03/2020 |
New Distribution channels to drive revenue growth from 2H FY2020 |
| 04/03/2020 |
Appendix 3G – Notification of issue, conversion or payment up of equity +securities |
| 27/02/2020 |
1H FY2020 Financial Results |
| 04/02/2020 |
Cellmid’s evolis patent to be granted in China |
| 29/01/2020 |
Cellmid Limited notes to the Appendix 4C |
| 06/01/2020 |
Key Midkine Antibody Patents granted in the US and Europe |
